Week 11 - Cancer

Question 1

Cyclophsphamide

Answer 1

Class: Alkylating Agent
Indication: Cancer
MOA: Form covalent bonds with DNA = stops replication
Adverse Effects: hair loss, sterility, haematology, myelosuppression (WBC)

Question 2

Doxorubicin

Answer 2

Class: Anthracyclines
Indication: Cancer
MOA: Insert betweek DNA bases = inhibits DNA, generate free radials = damage DNA
Adverse Effects: hair loss, sterility, haematology, myelosuppression (WBC)

Question 3

Methotrexate

Answer 3

Class: Antimetabolite
Indication: Cancer
MOA: S-Phase Specific, inhibits DHFR = decrease in purines (bases) = decrease in DNA production
Adverse Effects: hair loss, sterility, haematology, myelosuppression (WBC)

Question 4

Paclitaxel

Answer 4

Class: Taxane
Indication: Cancer
MOA: M-phase Specific, binds to microtubules and prevents the dissasembely, prevets chromosomes from pulling apart = no mitosis
Adverse Effects: hair loss, sterility, haematology, myelosuppression (WBC)

Question 5

Tamoxifen

Answer 5

Class: SERMs
Indication: Cancer (Breast)
MOA: Binds to estrogen receptors = stops estrogen from working = decreases cancer growth
Adverse Effects: hot flashes, vaginal discharge, and changes in menstruation, blood clots, uterine cancer

Question 6

Trastuzumab

Answer 6

Class: Monoclonal Antibody
Indication: Cancer
MOA: Bind to HER2 Receptors = stops dimerization = no activation = decreases proliferation of cancer
Adverse Effects:

Question 7

Lapatinib

Answer 7

Class: Kinase Inhibitor
Indication: Cancer
MOA: targets intracellular domain of HER 2 = stops activation = decreases proliferation
Adverse Effects: